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Abstract
Background: Understanding the risk factors for hearing loss is essential for designing the Belgian newborn hearing
screening programme. Accordingly, they needed to be updated in accordance with current scientific knowledge.
This study aimed to update the recommendations for the clinical management and follow-up of newborns with
neonatal risk factors of hearing loss for the newborn screening programme in Belgium.
Methods: A literature review was performed, and the Grading of Recommendations, Assessment, Development
and Evaluation (GRADE) system assessment method was used to determine the level of evidence quality and
strength of the recommendation for each risk factor. The state of scientific knowledge, levels of evidence quality,
and graded recommendations were subsequently assessed using a three-round Delphi consensus process (two
online questionnaires and one face-to-face meeting).
Results: Congenital infections (i.e., cytomegalovirus, toxoplasmosis, and syphilis), a family history of hearing loss,
consanguinity in (grand)parents, malformation syndromes, and foetal alcohol syndrome presented a ‘high’ level of
evidence quality as neonatal risk factors for hearing loss. Because of the sensitivity of auditory function to bilirubin
toxicity, hyperbilirubinaemia was assessed at a ‘moderate’ level of evidence quality. In contrast, a very low birth
weight, low Apgar score, and hospitalisation in the neonatal intensive care unit ranged from ‘very low’ to ‘low’
levels, and ototoxic drugs were evidenced as ‘very low’. Possible explanations for these ‘very low’ and ‘low’ levels
include the improved management of these health conditions or treatments, and methodological weaknesses such
as confounding effects, which make it difficult to conclude on individual risk factors. In the recommendation
statements, the experts emphasised avoiding unidentified neonatal hearing loss and opted to include risk factors
for hearing loss even in cases with weak evidence. The panel also highlighted the cumulative effect of risk factors
for hearing loss.
Conclusions: We revised the recommendations for the clinical management and follow-up of newborns exhibiting
neonatal risk factors for hearing loss on the basis of the aforementioned evidence-based approach and clinical
experience from experts. The next step is the implementation of these findings in the Belgian screening
programme.
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Background
The prevalence of bilateral hearing loss is substantial,
particularly in neonates admitted to the neonatal inten-
sive care unit (NICU) who frequently present with risk
factors for hearing loss. The prevalence of significant
bilateral hearing loss in this group is 1–3 %, which is 10
times higher than that in the well-baby nursery population
[1]. Furthermore, early intervention in hearing-impaired
children (aged 6 months or earlier) improved their
language and speech outcomes as well as their socio-
emotional development [2–4]. Therefore, universal
newborn hearing screening is widely recommended
[5–7] and implemented by governments or mother
and child health agencies.
Follow-up on toddlers’ hearing to diagnose potential
delayed-onset or progressive hearing loss in childhood is
a major issue. In 2007, the Joint Committee on Infant
Hearing (JCIH) released a unique list of risk indicators
associated with congenital/neonatal hearing loss and
delayed-onset/acquired or progressive hearing loss [6].
The JCIH recommends monitoring hearing, and speech
and language skills of all infants as well as performing
an audiological assessment at least once by 24–30
months of age in infants presenting with one or more
risk indicators from this list. Most newborn hearing
screening programmes and other recommendation state-
ments refer to the statements of the JCIH. However,
some authors have recently highlighted that the litera-
ture does not corroborate some risk indicators listed by
the JCIH, especially with respect to their relationship
with postnatal hearing loss [8, 9].
As in other regions, in Belgium, knowing the risk fac-
tors for hearing loss is essential for designing a newborn
hearing screening programme with different organisa-
tions and tests. According to the programme of the Féd-
ération Wallonie-Bruxelles (FWB, the French-speaking
area of Belgium) launched in 2006, different protocols
and neonatal hearing tests are performed depending on
the presence or absence of particular risk factors; in their
absence, an automated screening test of the cochlea is
performed, whereas an audiological assessment is recom-
mended in the presence of risk factor(s). This audiological
assessment comprises diagnostic tests that evaluate the
entire auditory function, including that of the central
auditory system. The identification of risk factors directs
neonates to the appropriate clinical pathway and thus
is essential.
Since the beginning of the newborn hearing screening
programme in the FWB, the risk factors were based on
the JCIH 2000 Position Statement [10] and the clinical
experience of professionals from the FWB. However, this
list of risk factors must be updated. Clinicians, specific-
ally otorhinolaryngologists and paediatricians, initially
requested this update because the removal, addition,
and/or clarification of some risk factors were required in
their clinical practice. New scientific findings and studies
were subsequently published, leading to the updated
JCIH Position Statement in 2007 [6].
The present study aimed to update the recommendation
for the clinical management of newborns with neonatal
risk factors for hearing loss on the basis of current scien-
tific knowledge. The recommendations were obtained by
performing a literature review and then grading the
evidence. Finally, the recommendations were validated by
the consensus of a panel of experts in the context of the
newborn hearing screening programme in the FWB. We
also present the recommended follow-up regime for
newborns with neonatal risk factors for hearing loss.
Methods
A consensus research procedure was used to update the
clinical management of newborns exhibiting neonatal
risk factors for hearing loss in the newborn hearing
screening programme in the FWB (Fig. 1).
Research context
To define the research context, objectives and research
questions were clarified using the population, interven-
tion, comparison, and outcomes (PICO) tool. This frame-
work was applied to each risk factor for hearing loss
used in the newborn hearing screening programme in
the FWB (Table 1).
Literature review
Between September 2014 and December 2014, we
reviewed the literature from the last 15 years for each
risk factor on the original list, and aimed to answer two
specific questions for each risk factor: (1) is it scientific-
ally pertinent to consider it as a risk factor for hearing
loss in the newborn hearing screening programme? and
(2) how is the risk factor defined?
We reviewed the PubMed database, the academic li-
brary of our institution, and the Cochrane Library for ar-
ticles in English and French. The following search terms
were used: [‘hearing loss’ OR ‘hearing impairment’ OR
‘deafness’] AND [‘newborn’ OR ‘neonatal’]. In addition,
each risk factor was searched (using Medical Subject
Headings (MeSH) terms or not). To the extent possible,
the literature review was limited to the last 15 years to
avoid the effects of changes in healthcare. Nonetheless,
if the literature review results were insufficient, the
search period was prolonged and the literature research
was extended to ‘neurodevelopmental outcomes’ on the
condition that the articles in question investigated hear-
ing loss. In cases in which few relevant papers were
found, bibliographies were used to find other references.
Review articles were included, but animal model studies
were excluded. The literature review revealed three
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potential risk factors not included in the original list that
were included in the analysis: congenital diaphragmatic
hernia, extracorporeal membrane oxygenation, and in-
haled nitric oxide.
When available in the selected papers, scientific infor-
mation about follow-up and postnatal hearing loss was
also reviewed for the risk factors from the original list
(i.e., what kinds of tests and timing are necessary?). To
ensure all risk factors were included in the list of the
FWB, a global literature review was performed using the
search terms ‘neonatal hearing loss’ and ‘postnatal hear-
ing loss’. We also searched the web to identify specific
documents from other newborn hearing screening pro-
grammes (i.e., grey literature).
Level of evidence
The main findings from each paper were summarised in
a table using the same framework for all risk factors.
The state of the scientific knowledge was subsequently
rated according to the Grading of Recommendations,
Assessment, Development and Evaluation (GRADE)
system [11]. The quality of evidence of each risk fac-
tor from the screening programme as a risk factor for
hearing loss was rated on the basis of the summary
of scientific literature. The level of quality was rated
as high, moderate, low, or very low. Considering the
PICO questions and study objectives, the studies reviewed
were mostly observational, starting at a ‘low’ level of
quality. Nevertheless, the rating can be upgraded or
downgraded according to the methodological elements
of the studies [12, 13].
Strength of the recommendations
Recommendations were formulated on the basis of the
literature review, quality of evidence, confidence in the
‘balance between desirable and undesirable effects’ of the
management strategies, required resources, and patients’
values and preferences (based on experts’ experience)
[14]. Each recommendation was graded as ‘recommend’
(strong) or ‘suggest’ (weak) [14]. Regarding the hearing
screening programme, ‘audiological assessment’ referred
to detailed hearing tests that should be implemented in
the presence of risk factors for hearing loss. Conversely,
‘screening test’ referred to the mass screening test per-
formed in the absence of a given neonatal risk factor.
Consensus method
The Delphi consensus method was used. Experts in paedi-
atrics, otorhinolaryngology, or newborn hearing screening
were recruited to participate in the panel of experts. The
final panel was comprised of six otorhinolaryngologists
(from university or non-university hospitals or hearing
rehabilitation centres), three paediatricians (from hospitals
or the Mother and Child Health Agency), and one neuro-
physiologist. These experts were not mandated by a gov-
ernment organisation and had no competing interests
related to this project; their sole motivation was to
improve the newborn hearing screening programme
Fig. 1 Flowchart of the methodological process
Table 1 Original neonatal risk factors for hearing loss in the
newborn hearing screening programme
Congenital infections:
In utero infection due to cytomegalovirus, toxoplasmosis, herpes,
rubella, and syphilis
Genetics of hearing loss:
Family history of hereditary hearing loss
Consanguinity in the first degree (i.e., parents are cousins)
Head or neck malformations, and by extension each polymalformation
syndrome known to include hearing loss
Maternal intoxication during pregnancy:
Poisoning (alcohol or drugs) by the mother during pregnancy
Specific conditions of the neonate:
Gestational age <36 weeks and/or birth weight <1,500 g
Apgar score of 0–6 at 5 min
Exchange transfusion (see reference curves) (hyperbilirubinaemia
or Rhesus incompatibility)
Medical care:
Neonatal intensive care unit stay >5 days
Newborn ototoxic medication
Assisted ventilation ≥24 h
Particular diseases:
Neurologic disease of the newborn (e.g., meningitis, etc.)
Endocrine disease of the newborn (e.g., thyroidal disease, etc.)
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in accordance with clinical realities and current
medical knowledge.
The consensus process was conducted between January
2015 and April 2015 in three rounds: two rounds of online
questionnaires and one face-to-face meeting. The first on-
line questionnaire aimed to validate the state of scientific
knowledge, the rated evidence for each neonatal risk
factor, and the proposed graded recommendations. All
pertinent scientific literature and the aforementioned
summary of the scientific papers were available for the
panel of experts. The online surveys were conducted using
SurveyMonkey®, and responses were coded on a Likert
scale from 1 to 5 (strongly agree, agree, neutral, disagree,
and strongly disagree, respectively). A consensus was
reached when at least two-thirds of the panel agreed or
disagreed, and when the mean Likert score was ≤2 or ≥4
[15]. A second questionnaire was administered for
discordant items related to recommendations; non-
consensual states of scientific knowledge and rated
evidence were adapted. The second online questionnaire
used stricter criteria with a narrow Likert scale from 1 to
3 (agree, neutral, and disagree, respectively), or only two
answer options were provided. The advantage of the on-
line survey was that each expert had the opportunity to
independently express his/her opinion. Finally, the panel
of experts discussed persistent discordances from the sec-
ond online questionnaire during the face-to-face meeting
to reach a final consensus.
Ethical concern
The ethical approval and informed consent are not
necessary according to Belgian regulations (the clinical
research Act - 2004 and the privacy Act - 1998).
Results
The rated levels of evidence and graded recommenda-
tions for each risk factor are summarised in Table 2.
Congenital infections
The prevalence of sensorineural hearing loss was higher
in neonates with congenital cytomegalovirus (CMV)
than those without risk factors for hearing impairment.
Observational studies (i.e., cohort and case–control
studies) reported a strong association in neonates be-
tween hearing impairment and congenital CMV infec-
tion regardless of whether the infection is symptomatic
or asymptomatic at birth [16, 17]. Moreover, studies fol-
lowing children during infancy also reported late-onset
or fluctuating hearing loss, highlighting the need for
audiological follow-up of infants with congenital CMV
during childhood [16–18]. Antiviral therapy in neonates
with congenital CMV has improved developmental
and hearing outcomes but has not resulted in total
recovery [19–21]. Antiviral therapy is recommended
for symptomatic neonates but not all congenital
CMV-infected neonates.
Similarly, congenital toxoplasmosis, syphilis, and ru-
bella are reportedly associated with neonatal hearing im-
pairment [22–27]. Nowadays, treatments for congenital
toxoplasmosis and syphilis, and rubella vaccine are
administered. Current results show no evidence for the
association between sensorineural hearing loss in neo-
nates with congenital toxoplasmosis or syphilis when
adequately treated [25, 28–31]. Nevertheless, follow-up
evaluation of hearing is recommended even for adequately
treated cases of toxoplasmosis or syphilis [25, 29]. Further-
more, infants with congenital rubella syndrome have an
elevated risk of hearing impairment. Therefore, neonatal
hearing evaluation and follow-up during childhood are
required for rubella-infected newborns [27, 32]. Nonethe-
less, widespread rubella vaccination has dramatically re-
duced the incidence of the disease. Consequently, hearing
impairment due to congenital rubella is now rare. How-
ever, the small number of cases is an issue in some studies,
resulting in low statistical power.
A systematic literature review evaluated the associ-
ation between congenital herpes infections and sensori-
neural hearing loss in neonates: only three studies were
identified, and limited evidence supports the assumption
that herpes simplex virus infection is a cause of sensori-
neural hearing loss [33]. Methodological limitations such
as inaccurate audiological information and the timing of
infection, and the imprecise timing of tests limit the
strength of this association.
Recommendations
The panel of experts recommends performing audio-
logical assessment during the neonatal period for new-
borns with congenital CMV, toxoplasmosis, rubella (i.e.,
congenital rubella syndrome), or syphilis infection.
The panel of experts recommends performing a hearing
screening test on newborns with congenital herpes
simplex virus.
The panel of experts clarifies that congenital infection
means that the newborn is infected, not merely maternal
seroconversion during pregnancy. Neonatal infection
should be identified by blood test (i.e., serologic confirm-
ation of toxoplasmosis, rubella, and syphilis) or urine
test (i.e., CMV infection) according to the infection.
This recommendation places high value on the level of
evidence of the risk factor for hearing loss and low value
on the treatment status of the neonate.
Genetics of hearing loss: family history, consanguinity,
syndromes, and malformations
In the literature, a family history of hearing loss is
often analysed with consanguinity [34–36]. However,
the state of genetics-related knowledge suggests a
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family history as a potential risk factor of hearing loss
in infants [37–39], particularly postnatal hearing loss
was recently demonstrated [40]. The literature clearly
demonstrates that the degree of parental consanguin-
ity is significantly and directly associated with the
prevalence of hearing loss in children [34, 41–43].
Furthermore, knowledge on genetics also indicates that
specific congenital syndromes are associated with hearing
loss; multiple websites and reviews have taken inventory
of such conditions [44–46]. Isolated malformations of
the pinnae such as preauricular skin tags and/or ear
pits are associated (significantly associated in two of
three studies) with a higher prevalence of hearing im-
pairment in most studies [47–49]. In addition, cleft
palate is associated with an increased prevalence of
conductive hearing loss in children even after surgical
repair [50, 51].
Recommendations
The panel of experts recommends performing audio-
logical assessment during the neonatal period in cases
with (a) a family history of congenital or early-onset her-
editary hearing loss (in parents, grandparents, siblings,
or cousins); (b) consanguinity of first or second degree
(i.e., parents or grandparents are cousins); and (c) mal-
formations and syndromes associated with hearing loss.
The panel of experts suggests audiological assessment
during the neonatal period in the presence of isolated
malformations of the pinnae.
Maternal intoxication during pregnancy
Maternal alcohol consumption in pregnancy, without
foetal alcohol syndrome, is not a risk factor for hearing
loss. Nevertheless, the prevalence of sensorineural and
conductive hearing loss is higher among children who
Table 2 Level of the quality of evidence and strength of the recommendation for each risk factor
Risk factor Quality of evidence Strength of recommendation
Congenital cytomegalovirus High Strong
Congenital toxoplasmosis High Strong
Congenital syphilis High Strong
Congenital rubella High Strong
Congenital herpes Very low Stronga
Family history of hearing loss Moderate Strong
Consanguinity Moderate Strong
Malformations and syndromes associated with hearing loss High Strong
Malformations of the pinnae (isolated) Low Weak
Maternal intoxication: foetal alcohol syndrome Moderate Strong
Maternal intoxication: drug abuse Very low Stronga
Very low birth weight Very low Strong
Birth asphyxia/Apgar score Low Strong
Hyperbilirubinaemia Moderate Strong
Neonatal intensive care unit stay Very low Weak
Assisted ventilation Very low Weak
Ototoxic drugs: aminoglycosides Very low Weak
Ototoxic drugs: loop diuretics Very low Weak
Extracorporeal membrane oxygenation Moderate Strong
Congenital diaphragmatic hernia Very low --b
Inhaled nitric oxide Very low --b
Neurologic disease: meningitis Moderate Strongc
Neurologic disease: intraventricular haemorrhage Very low Weak
Congenital hypothyroidism Moderate Strong
aStrongly recommended to not consider this as a risk factor for hearing loss
bThe panel decided to formulate no specific recommendation; because of the medical condition, ventilation will be performed (see recommendation for
assisted ventilation)
cOn the basis of their clinical experience, the panel decided to recommend an audiological assessment for newborns who need a neurologic consultation (e.g.,
convulsion, hypotonia, swallowing/feeding difficulties, or cranial nerve palsy)
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suffered from foetal alcohol syndrome than in the general
paediatric population [52–54]; the rates of hearing defects
were similar to those of newborns with craniofacial anom-
alies [55–57]. However, other maternal drug abuse during
pregnancy, such as cocaine, heroin, and methadone, is not
significantly associated with neonatal hearing impairment;
studies either failed to show evidence of a significant asso-
ciation or the effects of these drugs on auditory function
were inconsistent among studies [57–61].
Recommendations
The panel of experts recommends performing audio-
logical assessment during the neonatal period in the
presence of foetal alcohol syndrome.
The panel of experts recommends performing a hearing
screening test in neonates born to mothers who abused
drugs during pregnancy.
Specific neonatal conditions: prematurity or low birth
weight, Apgar scores, and hyperbilirubinaemia
Studies analysing low birth weight used different classifi-
cations of birth weight, such as low, very low, or ex-
tremely low birth weight. Most studies do not provide
evidence of a direct association between the neonatal
hearing loss and low birth weight, although the preva-
lence of sensorineural hearing loss is higher in low-
birth-weight neonates [62–66]. This can be explained by
the factors commonly related to low birth weight that
may have impacted hearing, such as assisted ventilation,
ototoxic drug administration, or hyperbilirubinaemia
[67, 68]. Most studies failed to account for these con-
founding variables in multivariable analysis. Therefore, it
weakens the strength of the association.
Another specific indicator of neonates is the Apgar
score, which is used as an indicator of birth asphyxia.
Studies analysing the association between Apgar score
with hearing loss were difficult to compare: the timing
of the Apgar score (i.e., 1, 5, or 10 min after birth) and
cut-off for birth asphyxia (i.e., Apgar score <3, ≤6 or <6, ≤7
or <7, etc.) varied considerably. In some studies, the Apgar
score was not associated with hearing loss, whereas in
others, a low Apgar score was associated with sensori-
neural hearing loss or abnormal hearing results, particu-
larly when measured 5 min after birth (i.e., scores <3 or ≤6,
or ≤7) [69–73]. Therefore, further studies are required to
clarify the duration of asphyxia, permanent characteristics
of hearing deficits related to the Apgar score and
birth asphyxia, and role of prematurity, which appears
to be a confounding factor [69, 74].
Hyperbilirubinaemia is frequently encountered in
neonates; severe and very severe cases must be treated
by phototherapy or exchange transfusion, respectively.
Hearing disabilities among infants with a history of
hyperbilirubinaemia are more prevalent than in the
general paediatric population [75, 76]. Indeed, the audi-
tory system is sensitive to bilirubin toxicity, which may
lead to bilirubin-induced neurologic dysfunction (BIND)
syndrome [77–82]. Some factors such as prematurity,
sepsis, and hypoxia may exacerbate bilirubin toxicity
[79, 80, 83, 84]. The most frequent type of auditory
damage is auditory neuropathy or dyssynchrony [80–82].
However, some hearing disabilities are transient and im-
prove with a decrease in the bilirubin level [85, 86].
Among preterm and full-term infants, the total serum bili-
rubin level does not appear to be a sensitive or specific
indicator for assessing the risk of auditory damage [83].
Moreover, auditory impairment may occur at total biliru-
bin levels considered ‘safe’ [80, 84]. Several studies men-
tioned that besides the bilirubin level, the duration of
exposure to bilirubin is related to hearing loss [80, 81, 83].
Therefore, risk assessment for auditory impairment in
cases of hyperbilirubinaemia should include several bio-
markers and auditory tests [80, 82, 84].
Very low birth weight/prematurity, a low Apgar score/
birth asphyxia, and hyperbilirubinaemia have a cumula-
tive effect, increasing the vulnerability of the brain and
auditory function [69, 74, 76, 78, 84].
Recommendations
The panel of experts recommends performing audio-
logical assessment during the neonatal period in cases of
(a) a very low birth weight (<1,500 g); (b) an Apgar score
of 0–6 at 5 min; and (c) early hyperbilirubinaemia (be-
fore day 2) requiring treatment or hyperbilirubinaemia
at any day of life requiring either intensive phototherapy
or exchange transfusion (based on reference curves).
By placing a high value on avoiding unidentified neonatal
hearing loss and because it is painless to perform an audio-
logical assessment, the panel of experts considers very low
birth weight a risk factor for hearing loss, even with a ‘very
low’ level of evidence. Moreover, in addition to exchange
transfusion, the panel considers early hyperbilirubinaemia
and intensive phototherapy a stronger risk factor than
that in the JCIH Position Statement (2007) [6]. The panel
stresses that improved phototherapy techniques and de-
vices lead to less frequent exchange transfusion treatments.
Therefore, they recommend considering early hyperbiliru-
binaemia and intensive phototherapy as neonatal risk
factors for hearing loss; they specifically choose not to
make a recommendation based on clinical markers. From
a broader perspective, the panel decided a strong recom-
mendation for these three conditions because of their
cumulative impact on auditory function susceptibility.
Medical care: NICU stay and use of ventilation or ototoxic
drugs
The JCIH Position Statement (2007) [6] considers a
NICU stay exceeding 5 days to be risk factor associated
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with permanent congenital, delayed, or progressive hear-
ing loss [6]. The association between NICU stay (i.e.,
admission or length of stay) and hearing loss is contro-
versial [73, 87–89]. Indeed, this indicator encompasses
multiple conditions and treatments and thus may not
reflect the complex and variable health situation of
neonates hospitalised in the NICU. Moreover, this
indicator is insufficiently considered by multivariable
statistical models.
Newborns admitted to the NICU can receive ventila-
tion support with endotracheal ventilation or nasal con-
tinuous positive airway pressure (CPAP). The prevalence
of hearing loss does not differ significantly between
mechanical ventilation and CPAP [90, 91]. Multivariable
analyses performed exclusively on preterm neonates in-
dicate that assisted ventilation lasting >5 days is an inde-
pendent risk factor for hearing loss and a risk of failed
hearing screening tests [74, 90]. However, a study of
newborns admitted to the NICU reported no significant
association between hearing loss and endotracheal assisted
ventilation or CPAP after adjusting for infants’ characteris-
tics and specialised medical procedures [73]. Univariate
analyses of different studies of newborns admitted to the
NICU showed no significant association between hearing
loss and assisted ventilation regardless of whether treat-
ment duration was mentioned. Therefore, current evi-
dence indicates that assisted ventilation is not obviously a
neonatal risk factor for hearing loss [92, 93].
Ototoxic drugs, specifically aminoglycosides and loop
diuretics, can be administered to newborns. However,
the association between aminoglycoside administration
and hearing loss is inconsistent among studies; most
studies reported no significant association with treatment
duration, total dose, or peak or trough serum concentra-
tions [94–98], whereas others reported ototoxicity of
aminoglycosides [88, 94, 95, 97–100], particularly on high-
frequency hearing [67, 99]. In some individuals, genetic
predisposition (i.e., a specific mutation of mitochondrial
DNA) is associated with aminoglycoside-induced and
non-syndromic sensorineural hearing loss, making them
particularly vulnerable to aminoglycoside toxicity [101].
The association between loop diuretics administered to
neonates and hearing loss is also inconsistent. However,
their (over) use in combination with other treatments
(e.g., aminoglycosides) appears to be associated with sen-
sorineural hearing loss [97, 102]. The transient character-
istic of loop diuretic-associated hearing loss has also been
discussed [67]. In those studies, the administration of
ototoxic drugs was supposed to be clinically appropriate;
inappropriate or uncontrolled drug administration may
have shown a different association with hearing loss.
Extracorporeal membrane oxygenation (ECMO) is an
extreme medical therapy used in critically ill newborns.
The incidence of sensorineural hearing loss reported
among infants who have received ECMO varies widely
among studies, but is higher than that in the general
paediatric population [103, 104]. However, these neonates
also received other extreme treatments and medical care
that could be related to sensorineural hearing loss. As the
hearing impairment reported in ECMO-treated neonates
may be late-onset or progressive, follow-up during child-
hood is recommended among those treated with ECMO
[103–105]. Studies about hearing loss frequently investi-
gated congenital diaphragmatic hernia and inhaled nitric
oxide in combination with ECMO. The incidence rates of
hearing loss associated with congenital diaphragmatic her-
nia are inconsistent in the literature [106–109]. Moreover,
such infants require other treatments and may suffer from
other conditions that are associated with or are considered
risk factors for sensorineural hearing loss. Furthermore,
there is no significant difference in the rate of sensori-
neural hearing loss between neonates treated with inhaled
nitric oxide and those treated with either 100 % oxygen or
simulated initiation treatment [110, 111]. The high preva-
lence of sensorineural hearing loss in neonates treated
with inhaled nitric oxide may be due to other conditions
or therapies. Hence, the relationship between hearing loss
and specific conditions and treatments in critically ill neo-
nates, such as ECMO, congenital diaphragmatic hernia,
and inhaled nitric oxide, require further investigation
despite the small numbers of cases.
Recommendations
The panel of experts recommends performing audio-
logical assessment during the neonatal period after
ECMO treatment.
The panel of experts suggests performing audiological
assessment during the neonatal period in cases of (a) a
NICU stay exceeding 5 days; (b) assisted ventilation lasting
at least 24 h; and (c) ototoxic drug (i.e., aminoglycosides
or loop diuretics) administration regardless of treatment
length.
The panel of experts’ recommendations regarding
NICU stay and ototoxic drugs are concordant with those
of the JCIH Position Statement (2007) [6]. They consider
assisted ventilation to include mechanical ventilation
(with endotracheal intubation) and CPAP. The 24-h dur-
ation of assisted ventilation was included as a criterion
of ill newborns. The panel proposed no specific recom-
mendations regarding neonates suffering from congeni-
tal diaphragmatic hernia or those treated with inhaled
nitric oxide; because of their medical condition, they will
be ventilated and thus should have an audiological assess-
ment as suggested.
Specific diseases: neurologic or endocrine diseases
Neurologic diseases in neonates include meningitis and
intraventricular haemorrhage. The risk of hearing loss
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due to meningitis varies widely in the literature, al-
though the reported rates are higher than those in the
general population; the long-term consequences such as
improvement/worsening of impairment also vary [112–
114]. Neonates with intraventricular haemorrhage, which
is specific to preterm infants, exhibit a slightly higher
prevalence of hearing loss, but an in-depth study high-
lights the role of white matter lesions over the intraven-
tricular haemorrhage on neurodevelopmental outcomes
such hearing loss [115–117].
Congenital hypothyroidism is strongly associated with
a higher prevalence of hearing loss than that in the gen-
eral population; reported cases of hearing loss are mostly
bilateral and of mild to moderate severity [118–120].
Phenylketonuria is a congenital endocrine disease that is
universally screened and treated; therefore, an associ-
ation between this disease, specifically if untreated, and
hearing loss is difficult to determine; the associations
of other endocrine diseases such the thrifty phenotype
hypothesis with hearing loss also require further
investigation [121, 122].
Recommendations
The panel of experts recommends performing audio-
logical assessment during the neonatal period in neonates
(a) who have suffered from meningitis or require a neuro-
logic consultation (i.e., convulsion, hypotonia, swallowing/
feeding difficulties, and cranial nerve palsy) and (b) with
congenital hypothyroidism.
Meningitis is confirmed by positive culture. The panel
of experts highlights some specific neurologic conditions
for paediatricians and otorhinolaryngologists, even with-
out rigorous evidence of an association with hearing
loss. This recommendation is based on the experts’
clinical experience.
The panel of experts suggests performing audiological
assessment during the neonatal period in neonates with
white matter lesions or intraventricular haemorrhage.
Specific elements emerging from the consensus
Cumulative effect of risk factors on hearing function
The panel of experts explicitly highlights situations in
which newborns exhibit more than one risk factor for
hearing loss; the prevalence and severity of hearing loss
increase with an increasing number of risk factors [123].
Therefore, such newborns require special attention.
Reassessment of risk factors
The panel insists these neonatal risk factors for hear-
ing loss are applicable during the first month of life
and should be reassessed in cases showing changes in
health condition during that period (e.g., in case of
readmission).
Recommended hearing tests and timing of the tests
(initial assessment and follow-up)
Timing of the initial audiological assessment
When an audiological assessment is suggested or recom-
mended, the panel of experts highlights the necessity to
perform (to the extent possible) hearing tests before hos-
pital discharge. In cases involving admission to the
NICU in particular, neonate hospitalisation is stressful
for the parents; therefore, they should not be required to
return to the hospital after discharge, if possible. The
goal is to avoid losses to follow-up and thus undiagnosed
cases. If audiological assessment is not performed before
discharge because of a short hospital stay, an outpatient
appointment should be made during the following month
at the latest. The appointment should be scheduled
before discharge.
Hearing tests for the initial audiological assessment
The panel of experts states that the audiological assess-
ment should at least include an auditory brainstem re-
sponse to assess the entire auditory brainstem pathway.
The tests should be chosen within the competency of
the otorhinolaryngologist in charge of the patient and in
accordance with the context and situation.
Follow-up
The panel of experts recommends audiological follow-
up for all children who have undergone audiological as-
sessment at birth; this follow-up should be performed
once between the ninth and twelfth months of life. The
panel of experts identifies two exceptions. First, children
with congenital CMV infection, a family history of con-
genital or early-onset hereditary hearing loss, a family
history of consanguinity of the first or second degree,
malformations and syndromes associated with hearing
loss, or those treated with ECMO should undergo audio-
logical follow-up every 4–6 months during their first
two years of life. Their hearing should be reassessed an-
nually between 2 and 6 years of age. Second, neonates
treated with ototoxic drugs should undergo audiological
follow-up once during the first 3 months of life. The
otorhinolaryngologist will judge the appropriate hearing
tests to perform during follow-up, depending on the
child’s risk factors and age.
Discussion
This study aimed to update the recommendations for
the clinical management and follow-up of children with
neonatal risk factors for hearing loss in the newborn
hearing screening programme in the FWB in Belgium.
To this end, we used methodological tools, including the
formulation of PICO questions, a literature review to
establish the state of scientific knowledge on risk factors
for hearing loss, the GRADE system assessment, and a
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consensus process with a panel of experts. The findings
of this study will ultimately improve clinical practice
through the earlier identification of newborns suffering
from hearing loss and adequate follow-up of children at
risk of delayed or late-onset hearing loss. Indeed, the
newborn hearing screening programme in Belgium is
based on the presence or absence of risk factor(s) for
hearing loss. Therefore, an accurate, sensitive, and well-
formulated list of neonatal risk factors for hearing loss
and recommendations for their management is essential.
However, the misidentification of risk factors for hearing
loss may lead to unnecessary assessment and stress for
parents; alternatively, newborns with neonatal hearing
loss may be overlooked because of having been sub-
jected to an insufficiently accurate audiological test.
Modification of the protocol design of the hearing
screening programme was unfeasible because it would
have required the analysis of complex technical ques-
tions such as available automated hearing tests and their
classification algorithms of normal versus unsatisfactory
results, organisational matters, cost-effectiveness, and
the global system of newborn hearing screening in
Belgium.
The state of knowledge about the neonatal risk factors
for hearing loss highlights the effects of treatment; in the
cases of some infectious risk factors such as congenital
CMV, toxoplasmosis, and syphilis infections, treatments
have modified the risk of developing hearing loss or pre-
vented hearing deterioration. When such diseases are
treated early after birth, congenitally infected children
have a lower risk of developing hearing loss than those
without treatment [20, 25, 29]. Therefore, the early iden-
tification of these risk factors is essential during prenatal
care or at birth at the latest to initiate treatment. The ru-
bella vaccination already changed the situation; because
of the vaccine and widespread immunization, congenital
rubella and hearing loss due to the disease have become
extremely rare in Belgium [27]. However, congenital ru-
bella must still be considered a risk factor in the hearing
screening programme, particularly for neonates born to
unvaccinated mothers. Likewise, the treatment of hyper-
bilirubinaemia reduces the risk of auditory damage.
Treatment reduces the risk of developing hearing loss in
some cases, whereas treatments such as ototoxic drugs,
ECMO, or ventilation are actually risk factors. Although
the development and evolution of these techniques or
treatments has led to better control, they must still
be used carefully and newborns should be monitored
closely. Because of these advances in healthcare, ana-
lysing risk factors for hearing loss on the basis of
studies performed decades ago is not recommended.
Therefore, to avoid inaccurate information, we limited
our literature review as much as possible to articles
published during the last 15 years. We also rated the
quality of evidence without including the treatment
effect to ensure a standardised perspective.
Drawing conclusions from published studies was
sometimes made difficult by the studies themselves. In
particular, multivariable analyses were not performed
systematically, and the numbers of children with hearing
impairment identified in the studies were limited. Firstly,
ill newborns frequently exhibit multiple risk factors such
as prematurity, NICU stay, ototoxic drug administration,
ventilation, etc. Hence, it is essential to consider the
actual impact of individual risk factors on hearing func-
tion. Therefore, univariate analyses were insufficient,
and multivariable models were not performed systemat-
ically. Second, the few cases of children with hearing
impairment also complicated the drawing of conclu-
sions; the low prevalence (a small percentage) of hearing
loss applied to small samples (usually <500 newborns)
led to the identification of only a few hearing-impaired
newborns. Random sampling may have dramatically af-
fected the numbers of identified children with hearing
impairment results and thus statistical power. Further-
more, there were multiple definitions of hearing loss and
a wide range of hearing tests and clinical criteria as well
as failure to consider other risk factors and inconsistent
results among studies in some cases.
To avoid bias in the literature review and determine
the states of scientific knowledge, we developed a thor-
ough and exhaustive approach. Although we investigated
the risk factors for hearing loss individually, when per-
tinent, we presented their cumulative effects on hearing
function by using a transversal approach. By making spe-
cific inquiries during the literature review, we detected
risk factors for hearing loss that would not have been
included in the original list. Because of this exhaustive
approach, we decided to add three risk factors to our
investigation: ECMO, congenital diaphragmatic hernia,
and inhaled nitric oxide. We strictly limited our research
to medical conditions and factors, although sociodemo-
graphic factors have been reported as other potential
risk factors for neonatal hearing loss [124]. Although the
association of sociodemographic factors with hearing
loss is poorly understood, they appear to be part of a
more complex relationship; that is, sociodemographic
factors appeared to be related to medical conditions or
risk factors already associated with hearing loss. These
kinds of risk factors were not included in the newborn
hearing screening programme but should be monitored
in the FWB to clarify their associations.
It is important to note that the studies retrieved
through the literature review were mostly observational
and thus started at a ‘low’ level of evidence quality.
Nonetheless, the GRADE system is flexible, as the qual-
ity of evidence can be rated on the basis of methodo-
logical criteria [125]. Indeed, we uprated the quality of
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evidence for some risk factors even though the studies
were exclusively observational [11]. However, rating the
quality of evidence involves making a judgment to choose
the best classification, whereas quality generally appears to
be distributed in a continuum; this arbitrariness implies
subjectivity. The transparency of the process and the de-
tailed summary of findings and arguments that arose
when rating the levels of evidence helped reduce this sub-
jectivity. With the aim of transparency, we mentioned the
arguments for the levels of evidence quality (Additional
file 1: Table S1).
The GRADE system is usually used in the clinical
management of therapies but can also be used in all
healthcare management decision making [13, 126]. Our
research objective did not focus on therapy or diagnostic
tests [127]. However, the Belgian Health Care Know-
ledge Centre used the GRADE system to identify risk
factors for a breast screening programme [128]. This
bolsters our confidence in the application of the GRADE
system in the present study. Nonetheless, the panel of
experts was not always comfortable with the application
of the GRADE system. They were all clinicians, and the
conflict between the evidence-based (i.e., epidemiological)
approach and their clinical experience (i.e., individual
approach) was challenging. Rating the quality of evidence
needed to be discussed specifically during the face-to-face
meeting; in particular, it was pointed out that a low quality
of evidence does not necessarily mean that the element
should not be considered a risk factor for hearing loss but
that the rating also results from the type of study, biases,
limitations, results, and methodology.
Beyond the quality of evidence, the recommendation
formulation considers other parameters such as benefit/
harm balance, resource use, and patients’ values and
preferences [14]. The panel of experts aided the transi-
tion from quality of evidence to recommendations owing
to their medical expertise and knowledge about the
subject and clinical practice. Indeed, in our context, the
inadequate identification of risk factors for hearing loss
affected the balance between misdiagnosis (or delayed
diagnosis), parental stress, and good allocation of hu-
man, technical, and financial resources (for the family
and society). In the absence of known risk factors for
hearing loss, a mass screening test is performed by pro-
fessionals with basic training (i.e., professionals not spe-
cialised in audiology); this requires less time and a less
expensive device, incurring less parental stress than an
audiological assessment. However, the automated oto-
acoustic emissions hearing screening technique imple-
mented in the screening programme is not sufficiently
sensitive in the presence of risk factor(s) and may not
identify neonatal hearing loss. Indeed, retrocochlear
hearing loss is more frequently encountered in the pres-
ence of a risk factor and may not be detected by an
otoacoustic emissions test (cochlear testing). Therefore,
an up-to-date list of risk factors and recommendations is
important to ensure the quality of the newborn hearing
screening programme and the health system sector re-
sponsible for hearing problems. In cases in which it was
unclear whether to include a risk factor in the updated
list, the panel of experts gave more weight to the fact
that audiological assessment is not painful and prevents
delayed diagnosis, even though this technique requires
more time for both the family and healthcare profes-
sionals and can incur parental stress; in such cases, they
developed a conservative approach and always consid-
ered unclear factors as risk factors for hearing loss. In
other words, the expert panel emphasises avoiding
delayed diagnosis or misdiagnosis, even if incurring un-
necessary hearing tests. According to the GRADE sys-
tem, the ‘patient important outcome’ must be included
in the recommendations [14]. Patients’ values and pref-
erences must also be included in the grading [14]. How-
ever, during the entire research process, more precisely
in the development of recommendations, patients’ or their
parents’/guardians’ perspectives were not consulted; their
input was only indirectly included according to the clinical
experiences of the panel of experts.
To foster rapid and complete acceptance, the recom-
mendations were written to be helpful and clear. The
next step after the publication of these updated recom-
mendations is to implement the updated list of risk fac-
tors for hearing loss in the programme. The challenge is
to convince paediatricians and otorhinolaryngologists to
implement this updated list and follow the recommenda-
tions by adapting their clinical practice. Having pertinent
and adequate recommendations but not using them
would negatively impact the newborn hearing screening
programme. Therefore, the dissemination of the updated
list, recommendations, and underlying scientific argu-
ments is strongly advised. They can be presented at na-
tional paediatric or otorhinolaryngology congresses and
directly to local hospital staff.
Conclusions
We updated the risk factors for hearing loss for the new-
born hearing screening programme in Belgium (FWB)
by combining an evidence-based approach and the clin-
ical experience of a panel of experts. Hence, we devel-
oped recommendations for the clinical management and
follow-up of newborns with neonatal risk factors for
hearing loss. As the recommended hearing tests and
follow-up regime differ depending on the presence or
absence of these risk factors in newborns, it is essential
to correctly identify newborns with neonatal risk fac-
tor(s) for hearing loss. The quality of evidence for the
risk factors for hearing loss ranged from ‘very low’, due
to the absence of scientific evidence or methodological
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weaknesses in studies, to ‘high’, mostly when the physio-
pathology of the risk factor on the auditory function is
understood. The recommendations were also graded
as ‘weak’ or ‘strong’. Moreover, the panel of experts
emphasises avoiding unidentified neonatal hearing loss
and recommends considering unclear factors as risk
factors for hearing loss. The next step is to imple-
ment these recommendations, which will improve the
ability of the hearing screening programme to identify
hearing loss in children and perform adequate follow-up
of children at risk of later onset; regular monitoring
of the screening programme should integrate this
updated list of risk factors.
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